NCT01010568 - Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Ofatumumab and Bendamustine

Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles

Trial Locations (1)

20007

Georgetown University, Washington D.C.